AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16122642 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 421
Study 11485054 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg Hypericum perforatum L. (St. John's Wort)
Number of subjects: 12
Study 11485054 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg Hypericum perforatum L. (St. John's Wort)
Number of subjects: 12
Study 11485054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9806319 — intervention group
Group type: EXPERIMENTAL
Intervention: All foods eaten with varying fat content (20%, 40%, 60%)
Number of subjects: 5
Study 9806319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch meal with varying fat content (20%, 40%, 60%)
Number of subjects: 5
Study 7841567 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive dosing
Number of subjects: 18
Study 7841567 — intervention group
Group type: COMPARATOR
Intervention: Empiric dosing
Number of subjects: 18
Study 3063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens
Number of subjects: 151
Study 3063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 151
Study 3063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 151
Study 3063541 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy, Estrogens, Radiotherapy
Number of subjects: 151
Study 29597104 — intervention group
Group type: EXPERIMENTAL
Intervention: ImpACT (Improving AIDS Care after Trauma) intervention; details on dosage and duration not specified
Number of subjects: 0
Study 27244298 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 27244298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Sleep CGI
Number of subjects: 0
Study 27244298 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy sleep onset delay scores
Number of subjects: 0
Study 24117522 — intervention group
Group type: EXPERIMENTAL
Intervention: Key-press action (self-action)
Number of subjects: 0
Study 24117522 — intervention group
Group type: COMPARATOR
Intervention: 85 dB noise burst (auditory prestimulus)
Number of subjects: 0
Study 22467778 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 5000
Study 22467778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 20573338 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Session Treatment (OST)
Number of subjects: 100
Study 17696986 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 336
Study 17696986 — intervention group
Group type: COMPARATOR
Intervention: No peer assessment
Number of subjects: 336
Study 16088037 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vardenafil
Number of subjects: 0
Study 16088037 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 0
Study 16088037 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 0
Study 16088037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12535027 — intervention group
Group type: EXPERIMENTAL
Intervention: L-cysteine-HCl 500 mg in two divided doses per day
Number of subjects: 47
Study 12535027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10792120 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg bolus followed by 0.015 mg/kg after 1.5, 3 and 4.5 h
Number of subjects: 13
Study 10792120 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 13
Study 10792120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8665630 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.8 mg.kg‐1
Number of subjects: 42
Study 8665630 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg.kg‐1 plus 1.5 ml of 0.5% heavy bupivacaine
Number of subjects: 42
Study 8665630 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of heavy bupivacaine 0.5%
Number of subjects: 42
Study 1316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leucocyte alpha-interferon treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study 6415738 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 2.4 g/day
Number of subjects: 60
Study 6415738 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day
Number of subjects: 60
Study 6415738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30351408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (≥1 dose)
Number of subjects: 312
Study 30351408 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete vaccination (all three doses)
Number of subjects: 312
Study 30351408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic HBV infection
Number of subjects: 312
Study 30351408 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective anti-HBs levels
Number of subjects: 312
Study 30351408 — intervention group
Group type: COMPARATOR
Intervention: Working in hospitals vs primary healthcare facilities
Number of subjects: 312
Study 29165853 — intervention group
Group type: EXPERIMENTAL
Intervention: PDMP opioid prescriptions (at least one prescription in the past year)
Number of subjects: 329
Study 29165853 — intervention group
Group type: EXPERIMENTAL
Intervention: PDMP opioid prescriptions (≥4 prescriptions)
Number of subjects: 329
Study 27695865 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil 5% topical foam, applied daily (1 ml) for 6 months
Number of subjects: 17
Study 25034716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3020
Study 25034716 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes mellitus
Number of subjects: 3020
Study 22658432 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg oral dose
Number of subjects: 0
Study 19640271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 750
Study 19640271 — intervention group
Group type: COMPARATOR
Intervention: Single photon emission tomography (SPECT)
Number of subjects: 750
Study 19640271 — intervention group
Group type: COMPARATOR
Intervention: Exercise tolerance testing (ETT)
Number of subjects: 750
Study 17458795 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge ppv (group 1 and group 2)
Number of subjects: 139
Study 17458795 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge ppv (group 3)
Number of subjects: 139
Study 17458795 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge ppv
Number of subjects: 139
Study 17458795 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge ppv
Number of subjects: 139
Study 16050857 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME‐MD Anxiety Module
Number of subjects: 1216
Study 16050857 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGH‐A
Number of subjects: 1216
Study 16050857 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSS
Number of subjects: 1216
Study 16050857 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP agreement with PRIME‐MD diagnosis
Number of subjects: 1216
Study 11641099 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9313600 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (two 15 mg doses, 30 minutes apart)
Number of subjects: 102
Study 9313600 — intervention group
Group type: COMPARATOR
Intervention: rTPA (intravenous front‐loaded, weight‐adjusted administration over 90 minutes)
Number of subjects: 102
Study 9313600 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Number of subjects: 102
Study 9313600 — intervention group
Group type: COMPARATOR
Intervention: rTPA
Number of subjects: 102
Study 8420615 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg of calcium daily)
Number of subjects: 200
Study 8420615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3945530 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 18
Study 3945530 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 18
Study 3945530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2742167 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5‐10 mg of 0.5% hyperbaric bupivacaine (Group A)
Number of subjects: 36
Study 2742167 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐12.5 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 36
Study 2742167 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 36
Study 31826853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept or ranibizumab (anti-VEGF agents)
Number of subjects: 2373
Study 31665143 — intervention group
Group type: EXPERIMENTAL
Intervention: JUMP Math
Number of subjects: 1146
Study 31665143 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual, problem-based approach
Number of subjects: 1146
Study 29798407 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self rehabilitation training (Group B)
Number of subjects: 98
Study 29798407 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt Daroff training (Group C)
Number of subjects: 98
Study 29798407 — intervention group
Group type: COMPARATOR
Intervention: No disposition (Control group A)
Number of subjects: 98
Study 25173761 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium folinate 20 mg/m(2)
Number of subjects: 0
Study 25173761 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium folinate 200 mg/m(2)
Number of subjects: 0
Study 25173761 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium folinate 300 mg/m(2)
Number of subjects: 0
Study 25173761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 0
Study 23435218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 19
Study 23435218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 19
Study 23435218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube ventilation (LTV)
Number of subjects: 19
Study 23435218 — intervention group
Group type: COMPARATOR
Intervention: No ventilation (NV)
Number of subjects: 19
Study 21651729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative tissue expansion using DynaClose Expansion System
Number of subjects: 34
Study 21651729 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexpanded radial forearm free-flap donor sites)
Number of subjects: 34
Study 17934184 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.5 mg/kg/day)
Number of subjects: 117
Study 17934184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17065669 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA600 (600 mg once daily)
Number of subjects: 181
Study 17065669 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA1200 (1200 mg once daily)
Number of subjects: 181
Study 17065669 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA1800 (1800 mg once daily)
Number of subjects: 181
Study 17065669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 14676592 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment (15 mg for ≤12 months, 30 mg for >12 months)
Number of subjects: 287
Study 10936785 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic random map-biopsy
Number of subjects: 102
Study 10936785 — intervention group
Group type: COMPARATOR
Intervention: RDE positive cases
Number of subjects: 102
Study 10936785 — intervention group
Group type: COMPARATOR
Intervention: RDE negative cases
Number of subjects: 102
Study 10072830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg Bid)
Number of subjects: 202
Study 10072830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet Bid)
Number of subjects: 202
Study 8335201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 12
Study 3511284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (120 mg in 50 ml saline) weekly for 6 weeks
Number of subjects: 47
Study 3511284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bacillus Calmette-Guerin
Number of subjects: 47
Study 3511284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin alone
Number of subjects: 47
Study 3511284 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection and fulguration alone (control group)
Number of subjects: 47
Study 3511284 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized study group (intravesical and percutaneous bacillus Calmette-Guerin)
Number of subjects: 47
Study 31010436 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA‐933
Number of subjects: 290
Study 31010436 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA‐191‐3p, miRNA‐933, and miRNA‐425‐3p
Number of subjects: 290
Study 28610968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-level NMES
Number of subjects: 66
Study 28610968 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-level NMES
Number of subjects: 66
Study 28610968 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 26742981 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (LN)
Number of subjects: 40
Study 26742981 — intervention group
Group type: COMPARATOR
Intervention: Open nephrectomy (ON)
Number of subjects: 40
Study 26742981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LN and ON)
Number of subjects: 40
Study 23167718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous oxytocin
Number of subjects: 180
Study 23167718 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone-only vaginal pessary
Number of subjects: 180
Study 21329837 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Kissing Crush (DK)
Number of subjects: 370
Study 21329837 — intervention group
Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 370
Study 18384910 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed advertisements for less healthy foods
Number of subjects: 309
Study 18384910 — intervention group
Group type: COMPARATOR
Intervention: Printed advertisements for healthy foods
Number of subjects: 309
Study 18384910 — intervention group
Group type: COMPARATOR
Intervention: Printed advertisements for non-food products
Number of subjects: 309
Study 16817266 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-round-needling
Number of subjects: 89
Study 16817266 — intervention group
Group type: COMPARATOR
Intervention: Western medication
Number of subjects: 89
Study 12556776 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg intravenous bolus followed by infusion at 8 mg/hour for 72 hours)
Number of subjects: 232
Study 12556776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 11524327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg IV just after the induction of anesthesia)
Number of subjects: 50
Study 11524327 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 50
Study 9315993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, every other day for group 1)
Number of subjects: 16
Study 9315993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, daily for group 2)
Number of subjects: 16
Study 9315993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 4-day washout period)
Number of subjects: 16
Study 8478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema (BE) examination
Number of subjects: 40
Study 8478168 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sonography before and after barium enema
Number of subjects: 40
Study 2881897 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 200 micrograms
Number of subjects: 12
Study 2881897 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms
Number of subjects: 12
Study 2881897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28935128 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training (n=17)
Number of subjects: 35
Study 28935128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-land aerobic training (n=18)
Number of subjects: 35
Study 28468794 — intervention group
Group type: COMPARATOR
Intervention: Continue MTX (group 1)
Number of subjects: 199
Study 28468794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspend MTX for 4 weeks before vaccination (group 2)
Number of subjects: 199
Study 28468794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspend MTX for 2 weeks before and 2 weeks after vaccination (group 3)
Number of subjects: 199
Study 28468794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspend MTX for 4 weeks after vaccination (group 4)
Number of subjects: 199
Study 26142239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0
Study 26142239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23208074 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg elemental calcium carbonate) plus Vitamin D (400 IU of vitamin D(3))
Number of subjects: 36282
Study 23208074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 21331975 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional manualized nine-session group intervention for complicated grief disorder
Number of subjects: 72
Study 21331975 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 72
Study 18177428 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial implants
Number of subjects: 41
Study 18177428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted implants
Number of subjects: 41
Study 18177428 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-arch fixed bridge
Number of subjects: 41
Study 16498589 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational eating disturbance intervention
Number of subjects: 95
Study 16498589 — intervention group
Group type: COMPARATOR
Intervention: Matched control sample
Number of subjects: 95
Study 12728080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/L)
Number of subjects: 36
Study 12728080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mg/L zinc)
Number of subjects: 36
Study 11203652 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported prostheses with tooth connection
Number of subjects: 18
Study 11203652 — intervention group
Group type: COMPARATOR
Intervention: Freestanding prostheses supported by implants
Number of subjects: 18
Study 8695090 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg trimethaphan
Number of subjects: 15
Study 8695090 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg trimethaphan
Number of subjects: 15
Study 8695090 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg trimethaphan
Number of subjects: 15
Study 8695090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1798889 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to sleep in the lateral position with the help of an alarm
Number of subjects: 60
Study 1798889 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged to learn lateral sleep posture on their own
Number of subjects: 60
Study 1798889 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a tongue retaining device (TRD)
Number of subjects: 60
Study 1798889 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study 31464703 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel
Number of subjects: 30
Study 31464703 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel followed by a 10% trichloroacetic acid (TCA) spot peel
Number of subjects: 30
Study 31464703 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel followed by a 20% trichloroacetic acid (TCA) spot peel
Number of subjects: 30
Study 29282098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining serum potassium ≥ 3.6 mEq/L (relaxed control)
Number of subjects: 160
Study 29282098 — intervention group
Group type: COMPARATOR
Intervention: Maintaining serum potassium ≥ 4.5 mEq/L (tight control)
Number of subjects: 160
Study 26333701 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-mediated food allergy confirmed through DBPCFC
Number of subjects: 180
Study 26333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-induced asthma exacerbations
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: Atopic dermatitis prevalence
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: Urticaria prevalence
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: Digestive symptoms prevalence
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: Rhinitis prevalence
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: sIgE level
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: Positive family history of atopy
Number of subjects: 180
Study 26333701 — intervention group
Group type: COMPARATOR
Intervention: FA in history
Number of subjects: 180
Study 26333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity and control of asthma
Number of subjects: 180
Study 23912284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic maintenance fluids (0.45% NaCl/5% dextrose)
Number of subjects: 63
Study 23912284 — intervention group
Group type: COMPARATOR
Intervention: Isotonic maintenance fluids (0.9% NaCl/5% dextrose)
Number of subjects: 63
Study 22031728 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual posteroanterior view chest radiograph for 4 years
Number of subjects: 154901
Study 22031728 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no interventions)
Number of subjects: 154901
Study 22031728 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of participants eligible for NLST
Number of subjects: 154901